Digoxin Inhibits Blood Vessel Density and HIF-1a Expression in Castration-Resistant C4-2 Xenograft Prostate Tumors

Clinical and Translational Science

Volumn 5, Issue 1, 2012, Pages 39-42

  Gayed, Bishoy A ^a   O'Malley, Katherine J ^a   Pilch, Jan ^b   Wang, Zhou ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Castration resistant prostate cancer; Digoxin; Hypoxia inducible factor 1a (HIF 1a)

Indexed keywords

ANDROGEN RECEPTOR; BROXURIDINE; CD31 ANTIGEN; DIGOXIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL DENSITY; BLOOD VESSEL PARAMETERS; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CELL LABELING; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD31; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DIGOXIN; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; ORCHIECTOMY; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ANDROGEN; RNA, MESSENGER; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MUS MUSCULUS;

EID: 84862777480     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/j.1752-8062.2011.00376.x     Document Type: Article

References (17)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. Ca Cancer J Clin. 2010; 60: 277-300.
2. Fitzpatrick JM, Anderson J, Sternberg CN, Fleshner N, Fizazi K, Rébillard X, Dogliotti L, Conti G, Turesson I, James N, et al. Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach. Crit Rev Oncol Hematol. 2008; 68(Suppl 1): S9-S22.
3. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F. EAU guidelines on prostate cancer. Eur Urol. 2008; 53(1): 68-80.
4. Stenkvist B, Bengtsson E, Eklund G, Eriksson O, Holmquist J, Nordin B, Westman-Naeser S. Evidence of a modifying influence of heart glucosides on the development of breast cancer. Anal Quant Cytol. 1980; 2(1): 49-54.
5. Stenkvist B. Is digitalis a therapy for breast carcinoma? Oncol Rep. 1999; 6: 493-496.
6. Platz E. Digoxin: a heart drug may help prevent or treat prostate cancer. Prostate Cancer Discovery. 2010; 6: 13-14.
7. Available at: Accessed January 1, 2012.
8. Svensson A, Azarbayjani F, Bäckman U, Matsumoto T, Christofferson R. Digoxin inhibits neuroblastoma tumor growth in mice. Anticancer Res. 2005; 25(1A): 207-212.
9. Yeh JY, Huang WJ, Kan SF, Wang PS. Inhibitory effects of digitalis on the proliferation of androgen dependent and independent prostate cancer cells. J Urol. 2001; 166(5): 1937-1942.
10. Lekas A, Lazaris AC, Deliveliotis C, Chrisofos M, Zoubouli C, Lapas D, Papathomas T, Fokitis I, Nakopoulou L. The expression of hypoxia-inducible factor-1alpha (HIF-1alpha) and angiogenesis markers in hyperplastic and malignant prostate tissue. Anticancer Res. 2006; 26(4B): 2989-2993.
11. Pipinikas CP, Carter ND, Corbishley CM, Fenske CD. HIF-1alpha mRNA gene expression levels in improved diagnosis of early stages of prostate cancer. Biomarkers. 2008; 13(7): 680-691.
12. Zhong H, Semenza GL, Simons JW, De Marzo AM. Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev. 2004; 28(2): 88-93.
13. Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, Rey S, Hammers H, Chang D, Pili R, et al. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci USA 2008; 105(50): 19, 579-19, 586.
14. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer. 1994; 57(3): 406-412.
15. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 1994; 54(10): 2577-2581.
16. Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor measurement in the nude mouse. J Surg Oncol. 1986; 31: 229-234.
17. Maeda K, Chung YS, Takatsuka S, Ogawa Y, Onoda N, Sawada T, Kato Y, Nitta A, Arimoto Y, Kondo Y, et al. Tumour angiogenesis and tumour cell proliferation as prognostic indicators in gastric carcinoma. Br J Cancer. 1995; 72: 319-323.